31P - Analysis of ROS1 rearrangement non-small cell lung cancer cell blocks from pleural effusion
- Wen-xian Wang (CN)
- Chunwei Xu (CN)
- Wu Zhuang (CN)
- Yuwang Tian (CN)
- Jianping Xu (CN)
- Meiyu Fang (CN)
- Yanping Chen (CN)
- Gang Chen (CN)
- Tangfeng Lv (CN)
- Yong Song (CN)
- Wen-xian Wang (CN)
Abstract
Background
ROS1 rearrangement in non-small cell lung cancer (NSCLC) patients has recently been identified as a driver gene event and patients benefi from crizotinib treatment. The aim of this study was to investigate the clinical value of ROS1 rearrangement non-small cell lung cancer (NSCLC) cell blocks from pleural effusion.
Methods
Two hundred and fifteen cases of ROS1 rearrangement non-small cell lung cancer (NSCLC) blocks cell from pleural effusion, and 404 cases of tissues were analysed by the reverse transcription polymerase chain reaction (RT-PCR) method. The consistency of ROS1 rearrangement was examined in 74 cases of patients with tissues and cell blocks.
Results
ROS1 rearrangement was found in 7 of 215 cell blocks (positive detection rate of 3.26%). ROS1 rearrangement was detected in 8 of 404 tissue blocks (positive detection rate of 1.98%). There were 71 cases of the 74 (95.95%) cases that had the same consistency as tissue block. ROS1 rearrangement was detected in 2 of 74 (2.70%) cell blocks, and 5 of 74 (6.76%) tissue blocks.
Conclusions
The rate of ROS1 rearrangement in cell blocks of NSCLC is higher than in matched tissue blocks. The patients with malignant pleural effusion are likely to tend to ROS1 rearrangement.
Legal entity responsible for the study
Wenxian Wang
Funding
Has not received any funding
Disclosure
All authors have declared no conflicts of interest.
